To this end, we firstly examined capabilities of SFN and miR-214 in modulation of c-MYC accumulation in response to cisplatin, which is a commonly prescribed chemotherapeutic drug for patients with lung cancer and is capable of inducing CSC phenotypes in NSCLCs [23]. This evidence concerns the gene MYC and lung carcinoma.